2019 novel coronavirus: an emerging global threat. Issue 2 (2nd April 2020)

• Record Type: Journal Article
• Authors: Columbus, Cristie; Brust, Karen B.; Arroliga, Alejandro C.
• Is Part Of: Proceedings. Volume 33:Issue 2(2020)
• Page Start: 209
• Page End: 212
• Publication Date: 2020-04-02
• Subjects: 2019-nCoV -- coronavirus -- Covid-19 -- epidemic -- infectious diseases; Medicine -- Periodicals; Medicine; Medicine -- Periodicals; Periodicals; Electronic journals; 616.005
• DOI: 10.1080/08998280.2020.1731272
• Languages: English
• ISSNs: 0899-8280

Abstract

Abstract: The coronavirus (CoV) epidemic that began in China in December 2019 follows earlier epidemics of severe acute respiratory syndrome CoV in China and Middle East respiratory syndrome CoV in Saudi Arabia. The full genome of the 2019 novel coronavirus (2019-nCoV) has now been shared, and data have been gathered from several case series. As of February 11, 2020, there have been 45, 182 laboratory-confirmed cases, the vast majority in China, with 1115 deaths, for an overall case-fatality rate of 2.5%. Cases have been confirmed in 27 countries. On average, each patient infects 2.2 other people. Symptomatic infection appears to predominantly affect adults, with a 5-day estimated incubation period between infection and symptom onset. The most common presenting symptoms are fever, cough, dyspnea, and myalgias and/or fatigue. All cases reported to date have shown radiographic evidence of pneumonia. 2019-nCoV is diagnosed by real-time reverse transcriptase polymerase chain reaction. Treatment is largely supportive, with regimens including antiviral therapy. Corticosteroids are not routinely recommended. Hand hygiene, prompt identification and isolation of suspect patients, and appropriate use of personal protective equipment are the most reliable methods to contain the epidemic.